NovaBay Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of NovaBay Pharmaceuticals generated cash of -$4,131,000, which is more than the previous year. Cash used in financing activities reached the amount of $1,910,000 last year. Net change in cash is therefore -$2,240,000.
Cash Flow
| 2014 | -15.05M | 2.59M | 7.38M |
|---|---|---|---|
| 2015 | -18.55M | -86K | 15.60M |
| 2016 | -12.13M | -160K | 19.42M |
| 2017 | -6.27M | -244K | 201K |
| 2018 | -5.56M | -44K | 5.59M |
| 2019 | -7.92M | -19K | 11.70M |
| 2020 | -4.72M | -26K | 9.76M |
| 2021 | -9.19M | -12.04M | 16.78M |
| 2022 | -6.65M | -112K | 4.63M |
| 2023 | -4.13M | -19K | 1.91M |
NBY Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 5.84M | 7.97M | 12.42M | 7.41M | 3.65M | 3.67M | 9.51M | 2.38M | 5.42M | 10.5M |
Operating activities | ||||||||||
Net income | -9.64M | -10.60M | -5.82M | -11.03M | -9.65M | -6.54M | -7.40M | -13.15M | -18.97M | -15.19M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 203K | 483K | 119K | 51K | 65K | 266K | 95K | 114K | 164K | 232K |
Stock-based compensation expense | 291K | 220K | 1.15M | 701K | 621K | 0 | 2.03M | 1.75M | 1.38M | 1.04M |
| Deferred income tax benefit | 291K | 220K | 1.15M | 701K | 621K | 0 | 2.03M | 1.75M | 1.38M | 1.04M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 1.21M | -305K | 452K | -317K | 2.31M | 774K | -1.50M | -1.58M | -299K | 555K |
Inventories | 560K | -217K | -243K | -116K | -212K | 198K | 369K | 472K | -751K | -451K |
Accounts payable | -1.15M | 667K | -163K | 321K | -862K | 516K | -260K | -2.16M | 1.65M | -252K |
Cash generated by operating activities | -4.13M | -6.65M | -9.19M | -4.72M | -7.92M | -5.56M | -6.27M | -12.13M | -18.55M | -15.05M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4.01M |
Investments In Property Plant And Equipment | -19K | -112K | -52K | -26K | -19K | -44K | -244K | -160K | -123K | -68K |
Acquisitions Net | 0 | 0 | -11.99M | 0 | 0 | 0 | 0 | 0 | 37K | 0 |
Cash generated by investing activities | -19K | -112K | -12.04M | -26K | -19K | -44K | -244K | -160K | -86K | 2.59M |
Financing activities | ||||||||||
Common Stock Issued | 3.56M | 4.73M | 16.68M | 5.22M | 6.69M | 5.58M | 249K | 13.64M | 11.51M | 227K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | -48K | 0 | 0 | 0 |
Repayments of term debt | 1.52M | -105K | -105K | -2.56M | 2.34M | 0 | 0 | -3.02M | 1.65M | 0 |
Cash used in financing activities | 1.91M | 4.63M | 16.78M | 9.76M | 11.70M | 5.59M | 201K | 19.42M | 15.60M | 7.38M |
Net Change In Cash | -2.24M | -2.13M | -4.44M | 5.01M | 3.75M | -15K | -6.31M | 7.12M | -3.04M | -5.07M |
Cash at end of period | 3.60M | 5.84M | 7.97M | 12.42M | 7.41M | 3.65M | 3.19M | 9.51M | 2.38M | 5.42M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |